Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Pharmacokinetics-Pharmacodynamics (PK-PD) Profile, Effectiveness and Safety of ATM-AVI in Special PopulationsRelease Date:Research Inflammation & Immunology China Impact of Rapid Diagnostic Tests (RDTs) on Treatment Pattern and Outcomes in Patients with Carbapenem-Resistant (CR) PathogensRelease Date:Research Inflammation & Immunology China Initiatives to Improve the Clinical Environment for Dermatologic Immunology, Inflammation, and Allergy CareRelease Date:Partner: The Japanese Society for Cutaneous Immunology and AllergyQuality Improvement Inflammation & Immunology Japan Real World, Long-term Efficacy Study of Ritlecitinib in Adult and Adolescent Patients with Severe Alopecia Areata in ChinaRelease Date:Research Inflammation & Immunology China Epidemiology and surveillance of Gram-negative infections caused by carbapenemase-producing organisms (CPOs) in the UKRelease Date:Research Internal Medicine United Kingdom Advancing Care for Patients with Advanced ALK+ Non-Small Cell Lung Cancer (NSCLC)Education Oncology All Quality Improvement Solutions for the Diagnosis and Management of Migraine and Headache DisordersQuality Improvement Internal Medicine Canada, USA Shared Decision Making in Hemophilia Patient CareRelease Date:Quality Improvement Rare Disease China Real-World Atopic Dermatitis: Italian Insights GrantRelease Date:Research Inflammation & Immunology Italy Title Grant Type Focus Area Country Application Due Date Clinical Updates and Strategies in the Treatment and Management of First-line BRAF V600E-mutant Metastatic Colorectal CancerRelease Date:Education Oncology USA Guidelines and Best Practices in the Holistic Management of Patients with Metastatic Urothelial Carcinoma (mUC)Education Oncology USA Improving Atopic Dermatitis and Alopecia Areata Quality of Care to Standardize ManagementRelease Date:Partner: Beijing Guangda Precision Medicine Research CenterQuality Improvement Inflammation & Immunology China COVID-19 Disease Burden on the Pediatric PopulationRelease Date:Education Vaccines USA Post-COVID Conditions: Potential Diagnosis, Testing, Management, and Ongoing ResearchRelease Date:Education Vaccines USA Optimizing Antimicrobial Stewardship Program in Saudi ArabiaRelease Date:Quality Improvement Inflammation & Immunology Saudi Arabia Shared Decision Making in Hemophilia Patient CareRelease Date:Quality Improvement Rare Disease USA Real-World Data Generation with Elranatamab in Relapsed/Refractory Multiple MyelomaRelease Date:Research Oncology All Pharmacokinetics-pharmacodynamics (PK-PD) of aztreonam-avibactam (ATM-AVI) in Special PopulationsRelease Date:Research Inflammation & Immunology Austria, Denmark, Finland, Germany, Italy, Netherlands, Norway, Romania, Spain, Sweden, United Kingdom Invasive Mold Infections (IMI) - Real-World Evidence from Treatment Outcomes with IsavuconazoleRelease Date:Research Inflammation & Immunology Australia, Germany, Israel, Italy, Spain, Switzerland Optimizing maternal immunization practice in Malaysia Indonesia Singapore PhilippinesRelease Date:Quality Improvement Vaccines Indonesia, Malaysia, Philippines, Singapore PARP-Inhibitor Combination Treatments: Biomarker Testing, Safety, and Efficacy in a Rapidly Changing Metastatic Prostate CancerRelease Date:Education Oncology USA